| Gene symbol | CD44 | Synonyms | CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL, HUTCH-1, HUTCH-I, Hermes-1, IN, LHR, MC56, MDU2, MDU3, MIC4, Pgp1 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11p13 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD44 molecule (IN blood group) | ||||
| Gene symbol | ERBB2 | Synonyms | CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19, NEU, NGL, TKR1, VSCN2, c-ERB-2, c-ERB2, p185(erbB2) | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | erb-b2 receptor tyrosine kinase 2 | ||||
| GTO ID | GTC2381 |
| Trial ID | NCT04430595 |
| Disease | Breast Cancer |
| Altered gene | GD2|HER2|CD44 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | 4SCAR-T cells |
| Generation | 4th |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Multi-4SCAR-T Therapy Targeting Breast Cancer |
| Year | 2020 |
| Country | China |
| Company sponsor | Shenzhen Geno-Immune Medical Institute |
| Other ID(s) | GIMI-IRB-20005 |
| Cohort 1 | |||||||
|
|||||||